Jorge Conde is a General Partner at Andreessen Horowitz, where he leads investments at the cross section of biology, computer science, and engineering. Jorge has more than 20 years of experience in leading, building, operating, and investing in life sciences and healthcare, with a broad range of operational roles in early-stage and commercial companies.
Prior to joining a16z, Jorge served as Chief Strategy Officer, Chief Financial Officer, and Chief Product Officer for Syros (NASDAQ: SYRS), which is advancing small molecules to control the expression of genes. Jorge was also co-founder and CEO of Knome, a human genome interpretation company acquired by Tute Genomics in 2015. Earlier in his career, Jorge worked in marketing and operations at MedImmune and as a biotechnology investment banker at Morgan Stanley.
Jorge holds an MBA from Harvard Business School, an M.S. from the Harvard-MIT Division of Health Sciences and Technology, and a B.A. in Biology from Johns Hopkins University.
Jorge was named one of the top 35 young innovators in the world by the MIT Technology Review and is a Henry Crown Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. He previously served on the board of the Museum of Science, Boston.
Jorge currently serves on the boards of the following Andreessen Horowitz portfolio companies: Aria, Asimov, Camp4, Dyno, Earli, EQRx, Komodo Health, Octant Bio, and Tmunity.